X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

GLTO

Closed

Galecto inc

3.41
0.00 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.41
Day's Range: 3.2801 - 3.65
Send
When Written:
 
2.05
Galecto Inc. is a clinical-stage biotechnology company that develops novel therapies for fibrosis and cancer. The company was founded in 2011 and is headquartered in Copenhagen, Denmark, with additional offices in Boston, Massachusetts, and Montreal, Canada. Galecto's lead drug candidate, GB0139, is a galectin-3 inhibitor that is being developed for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. The company also has a pipeline of other galectin inhibitors for the treatment of fibrosis and cancer, including GB1211 for myelofibrosis and GB2064 for pancreatic cancer. Galecto has raised over $300 million in funding from investors, including Novo Holdings, Morningside Ventures, OrbiMed Advisors, and Ysios Capital.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.188
X